Welcome to our dedicated page for Dr Reddys Labs news (Ticker: RDY), a resource for investors and traders seeking the latest updates and insights on Dr Reddys Labs stock.
Dr. Reddy's Laboratories Limited reports news on its global pharmaceutical business, including APIs, generics, branded generics, biosimilars and OTC medicines. Company updates cover product approvals and launches in regulated markets, such as generic semaglutide in Canada and OTC ophthalmic products in the U.S., as well as biosimilar development, regulatory submissions and strategic partnerships.
Recurring coverage also includes IFRS financial results, segment trends across Global Generics and Pharmaceutical Services and Active Ingredients, and market activity in the USA, India, Russia and CIS countries, China, Brazil and Europe. Related research releases include Aurigene Oncology updates on oncology programs and targeted protein degradation platforms.
Dr. Reddy’s Laboratories released its Q4 & Full Year FY24 Financial Results. In Q4FY24, revenues were ₹70,830 Mn, up 12% YoY, and FY24 revenues were ₹279,164 Mn, up 14% YoY. Gross margin was 58.6%. SG&A expenses increased by 14% YoY, R&D expenses were 9.7% of revenues. EBITDA was 26.4% of revenues. Profit before tax increased by 21% YoY in Q4FY24, and by 19% YoY for FY24. Profit after tax grew by 36% YoY in Q4FY24 and 24% YoY for FY24.
Dr. Reddy's Laboratories announced the launch of Doxycycline Capsules, 40 mg in the U.S., a generic equivalent of ORACEA® approved by the USFDA. The capsules contain immediate-release and delayed-release pellets, each totaling 40 mg of anhydrous doxycycline. This launch is a significant development for Dr. Reddy's in the U.S. market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.